Event info
Date:01 Jun
Time:9:00 - 11:00
Venue:Medicon Valley Alliance, Copenhagen
Contact person
Nicole Mastrell

Nicole Mastrell

Event Manager & PA to CEO

nm@mva.org

+45 6141 8634

MVA Good Morning Meeting – Developability and Immunosafety

Don’t let them threaten your drug development plans

Advancing your drug or vaccine candidate from late-stage discovery into the clinic is one of the most critical steps in development. To maximize your chances of success, it is essential to de-risk your drug candidates as early as possible.

This seminar will provide insights and solutions how to de-risk your development and to accelerate your path to FIH (First-in-Human) clinical studies.

Learn about how in silico and in vitro protein design and optimization tools can help you to identify and mitigate manufacturing, development and immunogenicity liabilities and to improve the quality and safety of your therapeutic proteins

Date: Wednesday 1st of June 2022
Time: 9:00 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium

 

SIGN UP

 

Program

9:00Networking, registration and light breakfast
9:30Welcome
David Munis Zepernick, Head of Member Engagement and Communication, Medicon Valley Alliance
Mattias Nyström, Account Manager, Lonza Biologics
9:35Developability and Immunosafety : Don’t let them threaten your drug development plans
Noel Smith, PhD, Head of Immunology, Early Development Services, Lonza
10:20Q&A
10:30Networking
11:00End of Good Morning Meeting

 

Speaker

 

Noel Smith, PhD, Head of Immunology, Early Development Services, Lonza

Noel completed his PhD and post-doctoral studies at the University of Cambridge in the field of metabolic disease.

He joined Lonza in 2009 and was involved in the setup of the human primary cell-based assay platform and now heads the Immunology group which develops assays to screen products for immunogenicity and immunotoxicity risk.

The Lonza Cambridge site focuses on supporting the development of new biotherapeutic proteins and vaccines with a particular focus on immunosafety, manufacturability and protein expression.

 

 

 

Organized byIn collaboration with